<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT</h1>
      <div class="meta">2025-09-15 13:09:26+00:00 UTC</div>
      <ul>
        <li>For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million net loss in Q2 2024.</li>
        <li>R&amp;D expenses were $34.7 million, compared to $14.9 million a year earlier, and G&amp;A expenses were $10.5 million, up from $7.8 million in Q2 2024.</li>
        <li>On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target.</li>
        <li>The company also announced that it received a $10 million milestone payment from Merck after the first patient was dosed in a lead collaboration program.</li>
        <li>(NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential.</li>
        <li>READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.</li>
        <li>Both JANX007 and JANX008 are currently enrolling patients in their respective Phase 1 clinical trials.</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/truist-initiates-coverage-on-janux-therapeutics-janx-with-a-buy-rating-100-pt/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/news/truist-initiates-coverage-janux-therapeutics-130926769.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=Truist+Initiates+Coverage+on+Janux+Therapeutics+%28JANX%29+with+a+Buy+Rating%2C+%24100+PT%0A%E2%80%A2+For+Q2+2025%2C+Janux+reported+a+net+loss+of+%2433.9+million%2C+which+is+an+increase+from+the+%246.0+million+net+loss+in+Q2+2024.%0A%E2%80%A2+R%26D+expenses+were+%2434.7+million%2C+compared+to+%241%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Ftruist-initiates-coverage-on-janux-therapeutics-janx-with-a-buy-rating-100-pt%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
